🇺🇸 FDA
Patent

US 10233235

Modulating the alternative complement pathway

granted A61KA61K38/00A61K38/1709

Quick answer

US patent 10233235 (Modulating the alternative complement pathway) held by The Regents of the University of Colorado, a Body Corporate expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
41
CPC classes
A61K, A61K38/00, A61K38/1709, A61K38/177, A61P